Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of preladenant versus placebo and rasagiline in Parkinson's disease with motor fluctuations
2009-015161-31Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of preladenant in Parkinson's disease (PD) (3 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline to week 12 in mean OFF time. Started Jun 2010; status: completed.
02
Drugs
preladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2009-015161-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015161-31.